Double minute

Boundless Bio Presents Research Showcasing its Imaging and Single-Cell Sequencing Platform for Extrachromosomal DNA (ecDNA) Detection at the 2020 American Society of Human Genetics (ASHG) Virtual Annual Meeting

Retrieved on: 
Monday, October 26, 2020
Oncology, Health, Genetics, Research, Science, Biotechnology, DNA, Biology, Carcinogenesis, Extrachromosomal DNA, Life sciences, Biotechnology, Branches of biology, Oncogene, Cancer, Single cell sequencing, Extrachromosomal circular DNA, Double minute

Boundless Bio , a biotechnology company developing innovative therapeutics directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today will present research highlighting powerful components of its proprietary Spyglass platform at the 2020 American Society of Human Genetics (ASHG) Annual Meeting.

Key Points: 
  • Boundless Bio , a biotechnology company developing innovative therapeutics directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today will present research highlighting powerful components of its proprietary Spyglass platform at the 2020 American Society of Human Genetics (ASHG) Annual Meeting.
  • The poster, titled A Robust Imaging and Single-Cell Sequencing Platform to Characterize Tumor Extrachromosomal DNA (ecDNA) in Response to Therapeutic Intervention , describes elements of Boundless Bios broad platform for interrogating ecDNA biology.
  • Tumors driven by oncogene amplification are aggressive, have poor prognosis, and have proven elusive for targeted therapies.
  • Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.

Boundless Bio Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Retrieved on: 
Wednesday, May 13, 2020
Biotechnology, Genetics, Health, Oncology, DNA, Extrachromosomal DNA, Cancer, Medicine, Oncogene, Branches of biology, Health, Double minute, Extrachromosomal circular DNA, ecDNA, Boundless Bio

Due to the virtual format, all oral, poster, and poster discussion sessions, as well as track-based Clinical Science Symposia, will be available on demand, beginning May 29 at 8 a.m. EDT, for registered attendees of the conference.

Key Points: 
  • Due to the virtual format, all oral, poster, and poster discussion sessions, as well as track-based Clinical Science Symposia, will be available on demand, beginning May 29 at 8 a.m. EDT, for registered attendees of the conference.
  • Extrachromosomal DNA, or ecDNA, are large circles of DNA containing genes that are outside the cells chromosomes and can make many copies of themselves.
  • They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.